Strategic asset sale Company recently divested its geneType assets to Rhythm Biosciences, signaling a strategic pivot that may open opportunities to engage on complementary genomics services, data partnerships, or contract research collaborations.

North American expansion Recent expansion of North American offices suggests increased regional activity and capacity; a sales approach could target local healthcare providers, clinics, and genomics labs seeking scalable software or data integration solutions.

Partnership momentum New collaboration with CancerIQ and joint sales marketing with Wellworks for You indicate a receptiveness to partnerships; explore co-sell opportunities, channel partnerships, and integrated offerings with allied health tech firms.

Platform launches Global launch of geneType on the EasyDNA platform highlights a move toward accessible genomics testing; potential upsell to enterprise clients for testing software, workflow automation, and analytics services.

Leadership & governance Recent CFO appointment and strengthened leadership signal a focus on financial discipline and scalable growth; engage with finance and procurement teams to offer cost-saving software solutions, licensing models, and predictable ROI.